ExploreWatchlistsPricing
  1. JP-listed companies
  2. Takeda Pharmaceutical Company Limited
  3. Financials
  4. Income before tax

Takeda Pharmaceutical Company Limited (4502)

Market cap
¥8.92T
P/E ratio
57.3x
Takeda develops and manufactures innovative medicines for gastrointestinal diseases, rare diseases, oncology, neuroscience, vaccines, and plasma therapies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Mar 31, 2025175,084+231.66%
Mar 31, 202452,791-85.93%
Mar 31, 2023375,090+23.97%
Mar 31, 2022302,571-17.38%
Mar 31, 2021366,235-702.82%
Mar 31, 2020-60,754-164.02%
Mar 31, 201994,896-56.31%
Mar 31, 2018217,205+51.52%
Mar 31, 2017143,346+18.92%
Mar 31, 2016120,539-182.88%
Mar 31, 2015-145,437-191.56%
Mar 31, 2014158,851+19.38%
Mar 31, 2013133,068-50.78%
Mar 31, 2012270,330

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat